Trust Size
$807M
Peak Price
$572.55
Current Price
$59.11
Return
+491.1%
Price Journey
What Happened
Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for serious hematologic diseases including rare blood disorders.
Disc Medicine became publicly traded through a reverse merger with Gemini Therapeutics in 2022. Gemini had originally gone public via a SPAC merger with FS Development Corp (sponsored by Foresite Capital) in February 2021. After Gemini's drug candidates failed, Disc Medicine used the reverse merger to gain a public listing for its hematology pipeline, which includes treatments for erythropoietic porphyria and other rare blood disorders. The stock has performed well on clinical trial progress.
Timeline
2020-08-07
S-1 Registration Filed
SEC Filing Details
CIK Number
1816736
Total SEC Filings
698
State of Incorporation
DE
Last Filing Date
2026-03-04
Business Location
San Francisco, CA
Trust/Asset Size
$807M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Disc Medicine